We came across a bullish thesis on Innoviva, Inc on Deep-Value Stocks’s Substack. In this article, we will summarize the bulls’ thesis on INVA. Innoviva, Inc’s share was trading at $22.48 as of February 11th. INVA’s trailing and forward P/E were 13.54 and 10.83 respectively according to Yahoo Finance.
Cherries/Shutterstock.com
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. INVA presents a compelling investment opportunity as a business in transition, currently priced for decline while undergoing a major transformation. Historically operating as a royalty-generator with minimal staff, the company earned roughly $400M in annual revenue and $364M in free cash flow, primarily from GSK-licensed drugs.
With underlying patents expiring in 2029–2030, Innoviva faced a looming cliff in royalty income, prompting management to build a new commercial operation, the Innoviva Specialty Therapeutics (IST) platform, focused on hospital-based, critical-care, and infectious disease treatments. The platform now generates nearly $150M in revenue, contributing about 40% of total revenue, with year-over-year growth of 46% and certain drugs, like XACDURO and Zoliflodacin, poised for substantial expansion. Once revenues surpass breakeven at ~$150M, incremental revenue is expected to convert into 60%+ free cash flow, demonstrating strong operating leverage.
The market currently values the business almost entirely on the remaining royalty stream (~$1.35B) while effectively pricing the new commercial platform for free, creating an asymmetric risk/reward opportunity. Innoviva’s balance sheet is fortified with significant liquidity, supporting the transition without jeopardizing operations.
Key catalysts include continued growth of core IST drugs, conversion of revenue into sustainable free cash flow, and potential interest from larger players as a takeover target. Risks remain around execution, dependence on GSK royalties in the near term, and past capital allocation missteps, though these are manageable. At the current market cap of $1.4B, investors gain robust downside protection from royalties while participating in the upside of a scaling commercial business, positioning Innoviva as a high-conviction, asymmetric investment with a fair value estimate around $35 per share.
Previously, we covered a bullish thesis on Eli Lilly and Company (LLY) by Kontra in May 2025, which highlighted the company’s leadership in obesity and diabetes therapeutics, strong revenue growth from GLP-1 treatments, robust margins, and disciplined capital returns. LLY’s stock price has appreciated by approximately 27.84% since our coverage. Deep-Value Stocks shares a different perspective but emphasizes Innoviva’s (INVA) transition from royalty-based revenue to a growing commercial pharmaceutical platform, offering asymmetric upside as new products scale.
Innoviva, Inc is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held INVA at the end of the third quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of INVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
